Oznur Sadioglu Cagdas
Oznur Sadioglu Cagdas has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Ayse Cefle
Division of Rheumatology, Department of Internal Medicine, Kocaeli University Faculty of Medicine, Kocaeli, Türkiye
3 shared publications - Ayten Yazici
Division of Rheumatology, Department of Internal Medicine, School of Medicine, Kocaeli University, Kocaeli, Turkey
3 shared publications - Neslihan Gokcen
Division of Rheumatology, Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Sakarya University, Sakarya, Türkiye
3 shared publications - Ali Osman Arisal
KOCAELİ ÜNİVERSİTESİ, TIP FAKÜLTESİ
1 shared publication - Aynur Karadenizli
Department of Medical Microbiology, Molecular Research and Antibody Laboratory, Faculty of Medicine, Kocaeli University, Kocaeli, Türkiye
1 shared publication - Duygu Temiz Karadag
Division of Rheumatology, Department of Internal Medicine, Kocaeli University Faculty of Medicine, İzmit, Turkey
1 shared publication
Latest Publications
- 22 May 2026
- Published by Caleo in Rheumatology Quarterly
SEROPREVALENCE AND ANTIBODY TITERS FOLLOWING COVID-19 INFECTION IN RHEUMATIC DISEASE PATIENTS: A COMPARATIVE CROSS-SECTIONAL STUDY
Objection: Data on the clinical course of COVID-19 and subsequent humoral immune responses in patients with rheumatic diseases remain limited. This study aimed to compare SARS-CoV-2 antibody responses between patients with rheumatic diseases and healthy controls and to identify clinical and treatment-related factors associated with antibody levels. Methods: This prospectively designed, single-center cross-sectional study included unvaccinated adults with rheumatoid arthritis, systemic lupus erythematosus, or ankylosing spondylitis who had a previous COVID-19 infection, along with age- and sex-matched healthy controls. COVID-19 was identified by PCR confirmation or compatible thoracic CT findings, and anti-spike and anti-nucleocapsid SARS-CoV-2 antibodies were assessed 1-6 months after infection using Elecsys immunoassays. Results: PCR-confirmed infection (P< .001) and several COVID-19-related symptoms, including headache, dyspnea, nausea/vomiting, fatigue, sore throat, and arthralgia, were significantly more frequent in the patient group (all P < .05). However, hospitalization and pulmonary involvement were each significantly more common in the control group (both P< .001). Intensive care admission was similarly low in both groups. Anti-S seropositivity was significantly higher in patients than in controls (P < .001), while anti-N seropositivity and anti-N/anti-S antibody titers were comparable between groups. Antibody levels did not differ significantly among rheumatic disease subgroups. However, both anti-N and anti-S titers were significantly higher in patients not receiving biologic therapy (both P < .001). Conclusion: Humoral immune responses following COVID-19 appeared to be largely preserved in patients with rheumatic diseases. Although anti-S seropositivity was higher in the patient group, antibody titers were lower among those receiving biologic therapy, suggesting a potential treatment-related effect on humoral immunity. Larger studies are warranted to confirm these findings.
- 22 May 2026
- Published by Caleo in Rheumatology Quarterly
SEROPREVALENCE AND ANTIBODY TITERS FOLLOWING COVID-19 INFECTION IN RHEUMATIC DISEASE PATIENTS: A COMPARATIVE CROSS-SECTIONAL STUDY
Objection: Data on the clinical course of COVID-19 and subsequent humoral immune responses in patients with rheumatic diseases remain limited. This study aimed to compare SARS-CoV-2 antibody responses between patients with rheumatic diseases and healthy controls and to identify clinical and treatment-related factors associated with antibody levels. Methods: This prospectively designed, single-center cross-sectional study included unvaccinated adults with rheumatoid arthritis, systemic lupus erythematosus, or ankylosing spondylitis who had a previous COVID-19 infection, along with age- and sex-matched healthy controls. COVID-19 was identified by PCR confirmation or compatible thoracic CT findings, and anti-spike and anti-nucleocapsid SARS-CoV-2 antibodies were assessed 1-6 months after infection using Elecsys immunoassays. Results: PCR-confirmed infection (P< .001) and several COVID-19-related symptoms, including headache, dyspnea, nausea/vomiting, fatigue, sore throat, and arthralgia, were significantly more frequent in the patient group (all P < .05). However, hospitalization and pulmonary involvement were each significantly more common in the control group (both P< .001). Intensive care admission was similarly low in both groups. Anti-S seropositivity was significantly higher in patients than in controls (P < .001), while anti-N seropositivity and anti-N/anti-S antibody titers were comparable between groups. Antibody levels did not differ significantly among rheumatic disease subgroups. However, both anti-N and anti-S titers were significantly higher in patients not receiving biologic therapy (both P < .001). Conclusion: Humoral immune responses following COVID-19 appeared to be largely preserved in patients with rheumatic diseases. Although anti-S seropositivity was higher in the patient group, antibody titers were lower among those receiving biologic therapy, suggesting a potential treatment-related effect on humoral immunity. Larger studies are warranted to confirm these findings.
- 28 December 2024
- Published by Springer Nature in Rheumatology International
- Vol. 45 (1) , 1-7
Monitoring disease activity and treatment response in ankylosing spondylitis: a retrospective study of hematologic inflammatory markers
Background: Hematological markers such as the neutrophil-lymphocyte ratio (NLR), monocyte-lymphocyte ratio (MLR), and platelet-lymphocyte ratio (PLR) are reliable indicators of inflammation. This study aims to investigate the potential role of these markers in assessing disease activity and treatment response in biologic-naive Ankylosing Spondylitis (AS) patients following the initiation of biological agents. Materials and methods: We designed this study as a retrospective cohort study with data obtained from a single center. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and The Bath Ankylosing Spondylitis Functional Index (BASFI) were used to evaluate disease activity and functional status of AS patients. Laboratory results at baseline, 3rd, 6th, and 12th months were documented. We calculated hematologic inflammatory markers for each visit. Mean platelet volume (MPV) and red cell distribution width (RDW) were also noted. Results: 54 biologic-naive patients with AS were included in this study. These inflammatory markers, except RDW, decreased over time. BASDAI, BASFI, CRP and ESR were significantly lower at 3rd, 6th, and 12th months compared to baseline values (all p < 0.001). Furthermore, NLR, PLR, and MLR showed a statistically significant decrease at 3rd, 6th, and 12th months compared to baseline values (all p < 0.001). However, when comparing the values at the 3rd, 6th, and 12th months, no statistically significant differences were observed. We also found no correlation between hematological inflammatory markers and BASDAI scores, despite observing some correlations between hematological markers and acute phase reactants. Conclusion: These markers could be valuable assessment tools for indicating disease activity and monitoring patients with AS after initiating biological treatment.
- 28 December 2024
- Published by Springer Nature in Rheumatology International
- Vol. 45 (1) , 1-7
Monitoring disease activity and treatment response in ankylosing spondylitis: a retrospective study of hematologic inflammatory markers
Background: Hematological markers such as the neutrophil-lymphocyte ratio (NLR), monocyte-lymphocyte ratio (MLR), and platelet-lymphocyte ratio (PLR) are reliable indicators of inflammation. This study aims to investigate the potential role of these markers in assessing disease activity and treatment response in biologic-naive Ankylosing Spondylitis (AS) patients following the initiation of biological agents. Materials and methods: We designed this study as a retrospective cohort study with data obtained from a single center. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and The Bath Ankylosing Spondylitis Functional Index (BASFI) were used to evaluate disease activity and functional status of AS patients. Laboratory results at baseline, 3rd, 6th, and 12th months were documented. We calculated hematologic inflammatory markers for each visit. Mean platelet volume (MPV) and red cell distribution width (RDW) were also noted. Results: 54 biologic-naive patients with AS were included in this study. These inflammatory markers, except RDW, decreased over time. BASDAI, BASFI, CRP and ESR were significantly lower at 3rd, 6th, and 12th months compared to baseline values (all p < 0.001). Furthermore, NLR, PLR, and MLR showed a statistically significant decrease at 3rd, 6th, and 12th months compared to baseline values (all p < 0.001). However, when comparing the values at the 3rd, 6th, and 12th months, no statistically significant differences were observed. We also found no correlation between hematological inflammatory markers and BASDAI scores, despite observing some correlations between hematological markers and acute phase reactants. Conclusion: These markers could be valuable assessment tools for indicating disease activity and monitoring patients with AS after initiating biological treatment.
- Open Access
- 28 February 2023
- Published by Kocaeli University in Acta Medica Nicomedia
- Vol. 6 (1) , 157-163
Antineutrophil cytoplasmic antibody serotypes may affect the clinical presentation of patients with granulomatosis with polyangiitis: a single-center, retrospective cross-sectional study
Objective: Granulomatosis with polyangiitis (GPA) is one of the systemic vasculitis included in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV). Clinical characteristics, ANCA serotypes, and their frequencies vary depending on the type of vasculitis. In this study, we aimed to investigate the link between ANCA serotypes and clinical variables documented at the time of admission. Methods: This study was a retrospective cross-sectional study including 40 patients with GPA. The demographic, clinical, laboratory, and radiological findings were extracted from medical records. Logistic Regression Analysis was performed to estimate the relationship between ANCA serotypes and other variables. Results: The mean age was 53.95±12.94 years, and there was a delay of 15.85±23.03 months in diagnosis. While constitutional symptoms were observed in 42% of patients, symptoms related to ear-nose-throat in 70%, lung in 87.5%, kidney in 62.5%, neurological findings in 30%, eye in 25%, skin in 25% and musculoskeletal system findings in 90% were noted. Male gender was seen more frequently in cANCA (60.7%) positive patients; however, pANCA-positive patients were mainly female (83.3%) (p=0.050). Delay in diagnosis was longer (p=0.001) and subglottic stenosis was more common (p
- 28 February 2023
- Published by Kocaeli University in Acta Medica Nicomedia
- Vol. 6 (1) , 157-163
Open AccessAntineutrophil cytoplasmic antibody serotypes may affect the clinical presentation of patients with granulomatosis with polyangiitis: a single-center, retrospective cross-sectional study
Objective: Granulomatosis with polyangiitis (GPA) is one of the systemic vasculitis included in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV). Clinical characteristics, ANCA serotypes, and their frequencies vary depending on the type of vasculitis. In this study, we aimed to investigate the link between ANCA serotypes and clinical variables documented at the time of admission. Methods: This study was a retrospective cross-sectional study including 40 patients with GPA. The demographic, clinical, laboratory, and radiological findings were extracted from medical records. Logistic Regression Analysis was performed to estimate the relationship between ANCA serotypes and other variables. Results: The mean age was 53.95±12.94 years, and there was a delay of 15.85±23.03 months in diagnosis. While constitutional symptoms were observed in 42% of patients, symptoms related to ear-nose-throat in 70%, lung in 87.5%, kidney in 62.5%, neurological findings in 30%, eye in 25%, skin in 25% and musculoskeletal system findings in 90% were noted. Male gender was seen more frequently in cANCA (60.7%) positive patients; however, pANCA-positive patients were mainly female (83.3%) (p=0.050). Delay in diagnosis was longer (p=0.001) and subglottic stenosis was more common (p